“…The established mechanistic, prognostic (ie, predicting adverse outcomes) and theragnostic (ie, predicting treatment responsiveness) values of these type-2 inflammatory biomarkers17–24 26 provide a strong basis for a clinical prediction model centred on these independent, additive, and, most importantly, modifiable risk factors. The current protocol extends our previous proof-of-concept23 24 work suggesting that traditional clinical risk factors can and should be adjusted for type-2 inflammatory biomarkers. Another novel aspect of our project is our intention to collaborate with a wide variety of authors and sponsors to form an international, data-driven, and not-for-profit consortium to support the development and validation of a robust clinical prediction model.…”